Published on
Jul 3, 2025
FDA Accelerates Approval of Sunvozertinib for EGFR Exon 20+ NSCLC
The FDA granted accelerated approval to sunvozertinib (Zegfrovy) for adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, whose disease has progressed after platinum-based chemotherapy …
Source:
Targeted Oncology
-
Pending
